Ann: AGM presentation and business and trading update, page-34

Another set of write-downs. Still carrying way too much Goodwill for the Nexstellis donkey - this is turning out to be worse than Genetics and we are still in the early days...

Disappointing read - but *finally* believable - less sugar more salt!

The books show clearly why no-one was interested in the business outside of MCS. None of it is standing up on it's own. Need more information about what happened with Dermology - someone dodging the dodge on revenue reporting??? New board - new standards and it was found out. Drop seems way to big for stocktaking error.

Too much spend to give away - no-one would want it; but really need the D2D campaign for Nexstellis to continue to gather steam and the marketing expenses to drop... A $44m EBITDA loss on fk all sales is going to destroy this company quickly. Bye-Bye $100m left over from the MCS sale WHAT A WASTE

Nexstellis team need to continue to work on their relationship with Health Care providers. Big feedback is that after the $25 a month introductory, people are facing a cost of over $100 (US!) to continue as not every health provider is subsidising.

Capital Return and reverse split will be interesting now as with these results and the weakness in SP - there will be people just holding on for that $cash, then without positive news; tank time.